retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Results: 28.3% Weight Loss
Description
While Exe4 was undetectable in the culture medium after transfection of Exe4 alone, the fusion with FCS and SP effectively enhanced secretion, with the combination of NGF-FCS2 yielding the highest Exe4 secretion in both cell lines
For one study (SURPASS-2), we used data both from the journal publication [25] and from a conference abstract [24]
doi: 10.2337/dc18-1094
Dose adjustment for maintenance: After reaching goal weight, some users reduce from 10-12mg to 6-8mg weekly while maintaining results
